← Leaderboards
David P Carbone
Ohio State University
$20,647,321
Attributed
$33,180,844
Total exposure
20
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.7M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$55,129,675 · 21
By mechanism
P50$23,412,351 · 6
UG1$12,879,038 · 2
U01$8,705,272 · 1
R01$6,876,319 · 3
U54$1,273,563 · 1
RC1$997,012 · 1
Top collaborators
- Mikhail M Dikov10 shared
- William E. Carson7 shared
- Arnab Chakravarti7 shared
- David Michael O'Malley7 shared
- Charles M Rudin7 shared
- Claire F Verschraegen7 shared
- Lynn M Matrisian5 shared
- Ticiana Leal4 shared
Most similar at Ohio State University
Same institution · by research overlap
- Claire F Verschraegen$7,194,564
- William E. Carson$27,905,247
- David Michael O'Malley$1,562,108
- Sarah H Tannehill-Gregg$548,500
- Michael C Ostrowski$13,472,116
Others in their field
Top investigators on “Malignant Neoplasm Of Lung”
- David Heimbrook · Leidos Biomedical Research, Inc.$349,639,893
- Richard K. Wilson · Washington University$202,666,376
- Walter John Curran · Thomas Jefferson University$94,674,902
- Jan C Buckner · Mayo Clinic Coll Of Medicine, Rochester$61,410,512
- Norman Wolmark · Nsabp Foundation, Inc.$54,610,124
- Leonard Freedman · Leidos Biomedical Research, Inc.$50,919,602
Research focus
Malignant Neoplasm Of LungClinical ResearchClinical TrialsProgramsTumorMolecularResearch PersonnelLung NeoplasmsMalignant NeoplasmsGrantPreclinical StudyTranslatingHuman SubjectTranslational ResearchFundingDrug DevelopmentAwardInnovationProteomicsGenomicsCollaborationsNon-Small-Cell Lung CarcinomaPeer ReviewTissues
Grant awards (108)
OSU as a Network Lead Academic Participating Site for the NCI NCTN$1,044,921
UG1 · FY2025 · CA
Targeting immunosuppressive adenosine in patients with metastatic non-small cell lung cancer$741,840
R01 · FY2025 · CA · contact PI
ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center$683,484
UG1 · FY2025 · CA
Project 05: Translational Therapeutics (TT)$60,535
P30 · FY2025 · CA · contact PI
OSU as a Network Lead Academic Participating Site for the NCI NCTN$1,274,922
UG1 · FY2024 · CA
Targeting immunosuppressive adenosine in patients with metastatic non-small cell lung cancer$704,749
R01 · FY2024 · CA · contact PI
ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center$683,484
UG1 · FY2024 · CA
Project 05: Translational Therapeutics (TT)$51,953
P30 · FY2024 · CA · contact PI
OSU as a Network Lead Academic Participating Site for the NCI NCTN$968,250
UG1 · FY2023 · CA
ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center$621,608
UG1 · FY2023 · CA
Targeting immunosuppressive adenosine in patients with metastatic non-small cell lung cancer$380,473
R01 · FY2023 · CA · contact PI
Project 05: Translational Therapeutics (TT)$51,950
P30 · FY2023 · CA · contact PI
OSU as a Network Lead Academic Participating Site for the NCI NCTN$1,083,717
UG1 · FY2022 · CA
ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center$734,389
UG1 · FY2022 · CA
Targeting immunosuppressive adenosine in patients with metastatic non-small cell lung cancer$559,834
R01 · FY2022 · CA · contact PI
Project 05: Translational Therapeutics (TT)$56,328
P30 · FY2022 · CA · contact PI
OSU as a Network Lead Academic Participating Site for the NCI NCTN$1,238,889
UG1 · FY2021 · CA
ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center$742,329
UG1 · FY2021 · CA
Targeting immunosuppressive adenosine in patients with metastatic non-small cell lung cancer$577,069
R01 · FY2021 · CA · contact PI
Project 05: Translational Therapeutics (TT)$61,572
P30 · FY2021 · CA · contact PI
OSU as a Network Lead Academic Participating Site for the NCI NCTN$1,099,920
UG1 · FY2020 · CA
ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center$750,806
UG1 · FY2020 · CA
Translational Therapeutics Research Program (TT)$48,694
P30 · FY2020 · CA · contact PI
OSU as a Network Lead Academic Participating Site for the NCI NCTN$1,099,919
UG1 · FY2019 · CA
ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center$852,400
UG1 · FY2019 · CA
Translational Therapeutics Research Program (TT)$53,293
P30 · FY2019 · CA · contact PI
Translational Therapeutics Research Program (TT)$65,564
P30 · FY2018 · CA · contact PI
Translational Therapeutics Research Program (TT)$4,572
P30 · FY2018 · CA · contact PI
Translational Therapeutics Research Program (TT)$2,399
P30 · FY2018 · CA · contact PI
Translational Therapeutics Research Program (TT)$2,390
P30 · FY2018 · CA · contact PI
Translational Therapeutics Research Program (TT)$2,022
P30 · FY2018 · CA · contact PI
Notch ligands in regulation of anti-cancer immunity$314,259
R01 · FY2017 · CA · contact PI
Translational Therapeutics Research Program (TT)$46,262
P30 · FY2017 · CA · contact PI
Notch ligands in regulation of anti-cancer immunity$314,259
R01 · FY2016 · CA · contact PI
Translational Therapeutics Research Program (TT)$36,301
P30 · FY2016 · CA · contact PI
Notch ligands in regulation of anti-cancer immunity$314,259
R01 · FY2015 · CA · contact PI
Clinical Trials Core$253,928
U54 · FY2015 · CA · contact PI
Notch ligands in regulation of anti-cancer immunity$304,831
R01 · FY2014 · CA · contact PI
Clinical Trials Core$254,747
U54 · FY2014 · CA · contact PI
Notch ligands in regulation of anti-cancer immunity$327,050
R01 · FY2013 · CA · contact PI
Clinical Trials Core$237,648
U54 · FY2013 · CA · contact PI
Clinical Trials Core$254,293
U54 · FY2012 · CA · contact PI
Clinical Trials Core$272,947
U54 · FY2011 · CA · contact PI
CAREER DEVELOPMENT PROGRAM$191,011
P50 · FY2011 · CA · contact PI
DEVELOPMENTAL RESEARCH PROGRAM$63,682
P50 · FY2011 · CA · contact PI
SPORE in Lung Cancer$2,300,000
P50 · FY2010 · CA · contact PI
Molecular Signatures of Lung Cancer$1,084,715
U01 · FY2010 · CA · contact PI
Molecular Signatures of Lung Cancer$510,045
U01 · FY2010 · CA · contact PI
Polymorphism and mutation spectrum in minorities with non-small cell lung cancer$310,552
RC1 · FY2010 · CA · contact PI
CAREER DEVELOPMENT PROGRAM$205,703
P50 · FY2010 · CA · contact PI
Polymorphism and mutation spectrum in minorities with non-small cell lung cancer$186,460
RC1 · FY2010 · CA · contact PI
DEVELOPMENTAL RESEARCH PROGRAM$68,578
P50 · FY2010 · CA · contact PI
SPORE in Lung Cancer$2,300,000
P50 · FY2009 · CA · contact PI
Molecular Signatures of Lung Cancer$716,165
U01 · FY2009 · CA · contact PI
Polymorphism and mutation spectrum in minorities with non-small cell lung cancer$500,000
RC1 · FY2009 · CA · contact PI
CAREER DEVELOPMENT PROGRAM$210,414
P50 · FY2009 · CA · contact PI
DEVELOPMENTAL RESEARCH PROGRAM$70,133
P50 · FY2009 · CA · contact PI
SPORE in Lung Cancer$2,300,000
P50 · FY2008 · CA · contact PI
Molecular Signatures of Lung Cancer$1,600,942
U01 · FY2008 · CA · contact PI
CAREER DEVELOPMENT PROGRAM$215,200
P50 · FY2008 · CA · contact PI
DEVELOPMENTAL RESEARCH PROGRAM$71,739
P50 · FY2008 · CA · contact PI
SPORE in Lung Cancer$2,300,000
P50 · FY2007 · CA · contact PI
Molecular Signatures of Lung Cancer$1,585,181
U01 · FY2007 · CA · contact PI
VEGF mediated signaling in tumor/host interactions$302,816
R01 · FY2007 · CA · contact PI
ADMINISTRATIVE CORE$191,311
P50 · FY2007 · CA · contact PI
CAREER DEVELOPMENT PROGRAM$105,449
P50 · FY2007 · CA · contact PI
DEVELOPMENTAL RESEARCH PROGRAM$70,300
P50 · FY2007 · CA · contact PI
Molecular Signatures of Lung Cancer$1,584,994
U01 · FY2006 · CA · contact PI
SPORE in Lung Cancer$1,234,000
P50 · FY2006 · CA · contact PI
VEGF mediated signaling in tumor/host interactions$311,860
R01 · FY2006 · CA · contact PI
SPORE in Lung Cancer$2,468,469
P50 · FY2005 · CA
Molecular Signatures of Lung Cancer$1,623,230
U01 · FY2005 · CA
VEGF mediated signaling in tumor/host interactions$319,365
R01 · FY2005 · CA
SPORE in Lung Cancer$2,592,479
P50 · FY2004 · CA
VEGF mediated signaling in tumor/host interactions$319,365
R01 · FY2004 · CA
SPORE in Lung Cancer$2,372,167
P50 · FY2003 · CA
VEGF mediated signaling in tumor/host interactions$319,365
R01 · FY2003 · CA
MOLECULAR THERAPEUTICS OF CANCER$111,740
K24 · FY2003 · CA
SPORE in Lung Cancer$2,480,919
P50 · FY2002 · CA
VEGF MEDIATED SIGNALING IN TUMOR/HOST INTERACTIONS$261,022
R01 · FY2002 · CA
MOLECULAR THERAPEUTICS OF CANCER$110,895
K24 · FY2002 · CA
MOLECULAR FINGERPRINTING OF LUNG CANCER$0
P50 · FY2002 · CA
CHROMOSOME TRANSLOCATIONS AND NOTCH3 SIGNALING PATHWAY$0
P50 · FY2002 · CA
ADENOVIRUS IN BRONCHIOLOALVEOLAR CELL LUNG CARCINOMA$0
M01 · FY2002 · RR
CONTINUOUS INFUSION TAXOL IN COMBINATION WITH THORACIC RADIATION IN LUNG CANCER$0
M01 · FY2002 · RR
IMMUNE RESPONSES &VACCINATION MUTANT RAS &P53 PEPTIDES IN CANCER$0
M01 · FY2002 · RR
SPORE in Lung Cancer$1,581,859
P50 · FY2001 · CA
VEGF MEDIATED SIGNALING IN TUMOR/HOST INTERACTIONS$254,918
R01 · FY2001 · CA
MOLECULAR THERAPEUTICS OF CANCER$109,975
K24 · FY2001 · CA
SPORE in Lung Cancer$18,938
P50 · FY2001 · CA
MOLECULAR FINGERPRINTING OF LUNG CANCER$0
P50 · FY2001 · CA
ADENOVIRUS IN BRONCHIOLOALVEOLAR CELL LUNG CARCINOMA$0
M01 · FY2001 · RR
ADENOVIRUS IN BRONCHIOLOALVEOLAR CELL LUNG CARCINOMA$0
M01 · FY2001 · RR
CONTINUOUS INFUSION TAXOL IN COMBINATION WITH THORACIC RADIATION IN LUNG CANCER$0
M01 · FY2001 · RR
CONTINUOUS INFUSION TAXOL IN COMBINATION WITH THORACIC RADIATION IN LUNG CANCER$0
M01 · FY2001 · RR
CONTINUOUS INFUSION TAXOL IN COMBINATION WITH THORACIC RADIATION IN LUNG CANCER$0
M01 · FY2001 · RR
IMMUNE RESPONSES &VACCINATION MUTANT RAS &P53 PEPTIDES IN CANCER$0
M01 · FY2001 · RR
IMMUNE RESPONSES &VACCINATION MUTANT RAS &P53 PEPTIDES IN CANCER$0
M01 · FY2001 · RR
IMMUNE RESPONSES &VACCINATION MUTANT RAS &P53 PEPTIDES IN CANCER$0
M01 · FY2001 · RR
ADENOVIRUS IN BRONCHIOLOALVEOLAR CELL LUNG CARCINOMA$0
M01 · FY2001 · RR
CHROMOSOME TRANSLOCATIONS AND NOTCH3 SIGNALING PATHWAY$0
P50 · FY2001 · CA
CHROMOSOME TRANSLOCATIONS AND NOTCH3 SIGNALING PATHWAY$0
P50 · FY2001 · CA
MOLECULAR FINGERPRINTING OF LUNG CANCER$0
P50 · FY2001 · CA
VEGF MEDIATED SIGNALING IN TUMOR/HOST INTERACTIONS$248,985
R01 · FY2000 · CA
MOLECULAR THERAPEUTICS OF CANCER$109,083
K24 · FY2000 · CA
ADENOVIRUS IN BRONCHIOLOALVEOLAR CELL LUNG CARCINOMA$592
M01 · FY2000 · RR
CONTINUOUS INFUSION TAXOL IN COMBINATION WITH THORACIC RADIATION IN LUNG CANCER$0
M01 · FY2000 · RR
IMMUNE RESPONSES &VACCINATION MUTANT RAS &P53 PEPTIDES IN CANCER$0
M01 · FY2000 · RR